Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and TRT for First-Line ES-SCLC
NCT07349225Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in small cell lung cancer (SCLC), sponsored by The Second Affiliated Hospital of Dalian Medical University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07349225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349225.